The estimated Net Worth of James W Stuckert is at least $49.8 Million dollars as of 27 June 2013. James Stuckert owns over 121,505 units of Sanara MedTech stock worth over $38,645,743 and over the last 21 years James sold SMTI stock worth over $11,166,483.
Sign up
James Stuckert SMTI stock SEC Form 4 insiders trading
James has made over 4 trades of the Sanara MedTech stock since 2012, according to the Form 4 filled with the SEC. Most recently James sold 121,505 units of SMTI stock worth $4,890,576 on 27 June 2013.
The largest trade James's ever made was selling 142,074 units of Sanara MedTech stock on 24 June 2013 worth over $5,925,907. On average, James trades about 8,940 units every 16 days since 2003. As of 27 June 2013 James still owns at least 1,153,260 units of Sanara MedTech stock.
You can see the complete history of James Stuckert stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Stuckert's mailing address?
James's mailing address filed with the SEC is 7308 SHADWELL PLACE, , PROSPECT, KY, 40059.
Insiders trading at Sanara MedTech
Over the last 5 years, insiders at Sanara MedTech have traded over $134,660 worth of Sanara MedTech stock and bought 963,856 units worth $8,000,005 . The most active insiders traders include Ronald T Nixon, James W Stuckert, and Zachary B. Fleming. On average, Sanara MedTech executives and independent directors trade stock every 148 days with the average trade being worth of $6,486,564. The most recent stock trade was executed by Zachary B. Fleming on 26 October 2021, trading 1,000 units of SMTI stock currently worth $34,040.
What does Sanara MedTech do?
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
What does Sanara MedTech's logo look like?
Complete history of James Stuckert stock trades at Royal Gold, Sanara MedTech, and Sanara MedTech
Sanara MedTech executives and stock owners
Sanara MedTech executives and other stock owners filed with the SEC include:
-
Zachary B. Fleming,
Chief Exec. Officer -
Shawn M. Bowman,
Co-COO & Pres of Wound Care -
Michael D. McNeil,
CFO & Corp. Sec. -
Cathy Bradshaw,
President of Wound Care Innovations, LLC -
Kenneth Thorpe,
Director -
Ann Salamone,
Director -
Robert DeSutter,
Director -
Zachary Fleming,
Co-Chief Operating Officers -
Shawn Bowman,
Co-Chief Operating Officers -
Michael McNeil,
Chief Financial Officer -
J Carmena,
Principal Executive Officer, Director -
Ronald Nixon,
Executive Chairman of the Board -
Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D.,
Pres of Telehealth Services -
Cathy Bradshaw,
Pres of Wound Care Innovations LLC -
Daniel F. Walsh Jr.,
Chief Commercialization Officer -
Carla Day,
Director of Customer & Sales Services -
Tricia Matteson,
Sr. Director of Marketing -
Dr. Jane A. Fore,
Chief Medical Officer -
Bill Fitzgerald,
Compliance Officer -
Callon Nichols,
Director of Investor Relations -
Ronald T. Nixon,
Exec. Chairman -
James W Stuckert,
Director -
Rebecca E Mc Mahon,
President of R&D